Clinical Trial Update: A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 long-term study of aripiprazole in pediatric patients with schizophrenia has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2017-06-28